查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529642

基因治疗市场规模、份额、趋势分析报告：按适应症、载体类型、给药途径、地区、细分市场预测，2024-2030

Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Acute Lymphoblastic Leukemia, Large B-cell Lymphoma), By Vector Type (Lentivirus), By Route Of Administration, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

基因治疗市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球基因治疗市场规模将达到182亿美元，2024年至2030年复合年增长率为18.88%。

基于基因治疗的发现数量的增加、该领域投资的增加以及基因治疗产品核准率的提高推动了市场的开拓。据世界卫生组织称，到 2025 年，每年将核准10 至 20 种新的细胞和基因疗法。

重组DNA技术的持续发展预计将在未来几年提高基因治疗的效率。因此，重组DNA技术的不断进步有望扩大基因治疗临床试验的数量。这些进步主要发生在各种基因编辑工具和表达系统的背景下，以加强产品的研究和开发。 CRISPR/Cas9 核酸酶、ZFN 和 TALEN 的出现使得简单而精确的基因组编辑成为可能。因此，近年来基因编辑领域出现了大量的研究活动，预计这也将对基因治疗市场的成长产生影响。

基因治疗市场的成长预计将大大受益于癌症盛行率的增加。每年癌症患者和相关死亡人数的持续增加强调了开发强有力的治疗解决方案的必要性。 2020年，全球约有1,810万新癌症患者。其中，男性 930 万，女性 880 万。肿瘤遗传学研究的持续进展预计将提供与癌症相关的分子特征的大量信息，这反过来又将支持正在进行的癌症治疗临床试验。

随着对强有力的疾病治疗的需求增加，公司专注于加速研究和开发在基因组层面上针对疾病原因的有效基因疗法。此外，美国FDA 持续透过一系列与产品製造相关的政策支持该领域的创新。 2020 年 1 月，FDA 发布了安全高效的产品製造和临床开发的六项最终指南。

此外，细胞和基因治疗的设施扩建是推动基因治疗市场成长的主要因素之一。一些用于基因治疗製造的自有设施和 CDMO 已开始投资以提高其生产能力，预计这将为市场参与者创造利润丰厚的机会。例如，2022 年 4 月，FDA核准了诺华北卡罗来纳州达勒姆工厂的商业许可。该批准授权这家占地 170,000 平方英尺的工厂生产、测试和销售 Zolgenma，并生产用于当前和未来临床试验的治疗产品。

基因治疗市场报告亮点

  • 到 2023 年，AAV 细分市场的销售贡献将达到 22%。多家生物製药公司为基于 AAV 的基因治疗产品开发提供病毒载体平台。
  • 有迹象表明，脊髓性肌肉萎缩症（SMA）领域在 2023 年以 46.8% 的份额占据市场主导地位。儘管脊髓性肌肉萎缩症很罕见，但它是婴幼儿最常见的致命遗传性疾病之一。
  • 地中海型贫血 B/SCD 预计在预测期内复合年增长率最快，达到 38.3%。 SCD 和 B 地中海贫血的基因治疗是基于基因改造造血干细胞移植。
  • 2023年，北美以65.2%的最大销售份额主导市场。在预测期内，就核准数量和收益而言，该地区预计将成为最大的基因疗法常规製造商。
  • 据估计，从 2024 年到 2030 年，欧洲将成为成长最快的地区。这是由于大量人口的医疗需求未被满足，以及对治疗罕见但日益流行的疾病的新技术的需求不断增长。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章 市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
  • 产业分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影响分析

第 4 章 依途径进行的业务分析

  • 基因治疗市场：依给药途径进行变异分析
  • 静脉
  • 其他的

第五章 依指标进行业务分析

  • 基因治疗市场：按适应症的波动分析
  • 急性淋巴性白血病
  • 遗传性视网膜疾病
  • 大B细胞淋巴瘤
  • 恶性黑色素瘤（病变）
  • 重症β地中海贫血/镰状细胞疾病 (ScD)
  • 脊髓性肌肉萎缩症（SMA）
  • 其他的

第 6 章向量类型的商业分析

  • 基因治疗市场：依载体类型进行变异分析
  • 慢病毒载体
  • 腺结合病毒(Aav) 载体
  • 逆转录病毒和γ逆转录病毒
  • 改良单纯疱疹病毒
  • 腺病毒载体
  • 其他的

第七章 区域业务分析

  • 基因治疗市场占有率：按地区划分，2023 年和 2030 年
  • 北美洲
  • 欧洲
  • 亚太地区
  • 世界其他地区

第八章 竞争格局

  • 公司分类
  • 策略规划
  • 2023 年企业市场分析
  • 公司简介
    • Amgen Inc.
    • Novartis AG
    • F. Hoffmann-La Roche
    • Gilead Sciences, Inc.
    • bluebird bio, Inc.
    • Bristol-Myers Squibb Company
    • Legend Biotech.
    • BioMarin.
    • uniQure NV
    • Merck &Co.
    • Sarepta Therapeutics, Inc.
    • Krystal Biotech, Inc
    • CRISPR Therapeutics.
Product Code: GVR-2-68038-179-5

Gene Therapy Market Growth & Trends:

The global gene therapy market is expected to reach USD 18.20 billion by 2030, registering a CAGR of 18.88% from 2024 to 2030, according to a new report by Grand View Research, Inc. The development of the market is owing to an increase in the number of gene therapy-based discoveries, increasing investment in this sector, and rising approval of gene therapy products. According to the WHO, 10 to 20 new cell and gene therapies are expected to be approved each year by 2025.

Continuous developments in recombinant DNA technology are anticipated to enhance the efficiency of gene therapy in the coming years. Hence, ongoing progresses in recombinant DNA technology are anticipated to expand the number of ongoing clinical trials for gene therapy. Primarily, these advancements are taking place in the context of various gene-editing tools and expression systems to augment the R&D for products. The advent of CRISPR/Cas9 nuclease, ZFN, and TALEN allows easy & precise genome editing. As a result, in recent times, the gene-editing space has witnessed a substantial number of research activities, which, in turn, is expected to influence the growth of the gene therapy market.

The growth of the gene therapy market is expected to be majorly benefitted from the increasing prevalence of cancer. The ongoing increase in cancer patients and related death per year emphasizes the essential for the development of robust treatment solutions. In 2020, there were around 18.1 million new cases of cancer worldwide. 9.3 million of these cases involved men, while 8.8 million involved women. Continuing developments in tumor genetic studies have delivered substantial information about cancer-related molecular signatures, which in turn, is expected to support ongoing clinical trials for cancer therapeutics.

With rising demand for robust disease treatment therapies, companies have focused their efforts to accelerate R&D for effective genetic therapies that target the cause of disease at a genomic level. . Furthermore, the U.S. FDA provides constant support for innovations in this sector via a number of policies with regard to product manufacturing. In January 2020, the agency released six final guidelines on the manufacturing and clinical development of safe and efficient products.

Furthermore, facility expansion for cell and gene therapies is one of the major factors driving the gene therapy market growth. Several in-house facilities and CDMOs for gene therapy manufacturing have begun investing to enhance their production capacity, which, in turn, is anticipated to create lucrative opportunities for market players. For instance, in April 2022, the FDA approved commercial licensure approval to Novartis for its Durham, N.C. site. This approval permits the 170,000 square-foot facility to make, test, and issue commercial Zolgensma, as well as manufacture therapy products for current & upcoming clinical trials.

Gene Therapy Market Report Highlights:

  • The AAV segment shows a significant revenue contribution of 22% in 2023. Several biopharma companies are offering their viral vector platform for the development of AAV-based gene therapy product.
  • By indication, the spinal muscular atrophy (SMA) segment dominated the market in 2023 with a share of 46.8%. Although SMA is a rare disorder, it is one of the most common fatal inherited diseases of infancy.
  • The Beta-Thalassemia Major/SCD segment is anticipated to register the fastest CAGR of 38.3% over the forecast period. Gene therapy for SCD and B-thalassemia is based on transplantation of gene-modified hematopoietic stem cells.
  • North America dominated the market in 2023 with the largest revenue share of 65.2% in 2023. This region is expected to become the largest routine manufacturer of gene therapy in terms of the number of approvals and revenue generated during the forecast period.
  • Europe is estimated to be the fastest-growing regional segment from 2024 to 2030. This is attributed to its large population with unmet medical needs and increasing demand for novel technologies in the treatment of rare but increasingly prevalent diseases.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Indication
    • 1.2.2. Route of Administration
    • 1.2.3. Vector Type
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
  • 1.7. Primary Research
  • 1.8. Information or Data Analysis
  • 1.9. Market Formulation & Validation
  • 1.10. Market Model
  • 1.11. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Robust Gene Therapy Pipeline
      • 3.2.1.2. Introduction Of Technological Advancements
      • 3.2.1.3. Increasing Investment From Companies And Partnerships
      • 3.2.1.4. Growing Prevalence Of Target Diseases And Increased Demand For Innovative Medicine
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Absence Of Effective Diagnosis Framework
      • 3.2.2.2. High Prices Of Gene Therapy
    • 3.2.3. Market Opportunity Analysis
      • 3.2.3.1. Rising Investment For Adoptive T-Cell Transfer Approaches Of Disease Treatment
      • 3.2.3.2. Facility Expansion For Cell And Gene Therapies
      • 3.2.3.3. Technological Advancements In Manufacturing Vectors
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Route of Administration Business Analysis

  • 4.1. Gene Therapy Market: Route of Administration Movement Analysis
  • 4.2. Intravenous
    • 4.2.1. Intravenous Market, 2018 - 2030 (USD Million)
  • 4.3. Others
    • 4.3.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Indication Business Analysis

  • 5.1. Gene Therapy Market: Indication Movement Analysis
  • 5.2. Acute Lymphoblastic Leukemia
    • 5.2.1. Acute Lymphoblastic Leukemia Market, 2018 - 2030 (USD Million)
  • 5.3. Inherited Retinal Disease
    • 5.3.1. Inherited Retinal Disease Market, 2018 - 2030 (USD Million)
  • 5.4. Large B-Cell Lymphoma
    • 5.4.1. Large B-Cell Lymphoma Market, 2018 - 2030 (USD Million)
  • 5.5. Melanoma (lesions)
    • 5.5.1. Melanoma (lesions) Market, 2018 - 2030 (USD Million)
  • 5.6. Beta-Thalassemia Major/Sickle Cell Disease (Scd)
    • 5.6.1. Beta-Thalassemia Major/Sickle Cell Disease (Scd) Market, 2018 - 2030 (USD Million)
  • 5.7. Spinal Muscular Atrophy (SMA)
    • 5.7.1. Spinal Muscular Atrophy (SMA) Market, 2018 - 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Vector Type Business Analysis

  • 6.1. Gene Therapy Market: Vector Type Movement Analysis
  • 6.2. Lentiviral Vectors
    • 6.2.1. Lentiviral Vectors market, 2018 - 2030 (USD Million)
  • 6.3. Adeno-Associated Viral (Aav) Vectors
    • 6.3.1. Adeno-Associated Viral (Aav) Vectors market, 2018 - 2030 (USD Million)
  • 6.4. RetroVirus & gamma RetroVirus
    • 6.4.1. RetroVirus & gamma RetroVirus market, 2018 - 2030 (USD Million)
  • 6.5. Modified Herpes Simplex Virus
    • 6.5.1. Modified Herpes Simplex Virus market, 2018 - 2030 (USD Million)
  • 6.6. Adenovirus Vectors
    • 6.6.1. Adenovirus Vectors market, 2018 - 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Others market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Gene Therapy Market Share By Region, 2023 & 2030
  • 7.2. North America
    • 7.2.1. North America Gene Therapy Market, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Target disease prevalence
      • 7.2.2.3. Competitive Scenario
      • 7.2.2.4. Regulatory Framework
      • 7.2.2.5. U.S. Gene Therapy Market, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Target disease prevalence
      • 7.2.3.3. Competitive Scenario
      • 7.2.3.4. Regulatory Framework
      • 7.2.3.5. Canada Gene Therapy Market, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Key Country Dynamics
      • 7.2.4.2. Target disease prevalence
      • 7.2.4.3. Competitive Scenario
      • 7.2.4.4. Regulatory Framework
      • 7.2.4.5. Mexico Gene Therapy Market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Gene Therapy Market, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Target disease prevalence
      • 7.3.2.3. Competitive Scenario
      • 7.3.2.4. Regulatory Framework
      • 7.3.2.5. UK Gene Therapy Market, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Target disease prevalence
      • 7.3.3.3. Competitive Scenario
      • 7.3.3.4. Regulatory Framework
      • 7.3.3.5. Germany Gene Therapy Market, 2018 - 2030 (USD Million)
    • 7.3.4. Switzerland
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Target disease prevalence
      • 7.3.4.3. Competitive Scenario
      • 7.3.4.4. Regulatory Framework
      • 7.3.4.5. Switzerland Gene Therapy Market, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Gene Therapy Market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target disease prevalence
      • 7.4.2.3. Competitive Scenario
      • 7.4.2.4. Regulatory Framework
      • 7.4.2.5. Japan Gene Therapy Market, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target disease prevalence
      • 7.4.3.3. Competitive Scenario
      • 7.4.3.4. Regulatory Framework
      • 7.4.3.5. China Gene Therapy Market, 2018 - 2030 (USD Million)
    • 7.4.4. Australia
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target disease prevalence
      • 7.4.4.3. Competitive Scenario
      • 7.4.4.4. Regulatory Framework
      • 7.4.4.5. Australia Gene Therapy Market, 2018 - 2030 (USD Million)
  • 7.5. Rest of the world
    • 7.5.1. Rest of the world Gene Therapy Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2023
  • 8.4. Company Profiles
    • 8.4.1. Amgen Inc.
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. Novartis AG
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. F. Hoffmann-La Roche
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. Gilead Sciences, Inc.
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. bluebird bio, Inc.
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. Bristol-Myers Squibb Company
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. Legend Biotech.
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. BioMarin.
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. uniQure N.V.
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. Merck & Co.
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives
    • 8.4.11. Sarepta Therapeutics, Inc.
      • 8.4.11.1. Overview
      • 8.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Strategic Initiatives
    • 8.4.12. Krystal Biotech, Inc
      • 8.4.12.1. Overview
      • 8.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.12.3. Product Benchmarking
      • 8.4.12.4. Strategic Initiatives
    • 8.4.13. CRISPR Therapeutics.
      • 8.4.13.1. Overview
      • 8.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.13.3. Product Benchmarking
      • 8.4.13.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Tables
  • Table 3 List of Secondary Sources
  • Table 4 List of Abbreviations
  • Table 5 Global Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
  • Table 6 Global Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 7 Global Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 8 Global Gene Therapy Market by Region, 2018 - 2030 (USD Million)
  • Table 9 North America Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
  • Table 10 North America Gene Therapy Market by Country, 2018 - 2030 (USD Million)
  • Table 11 North America Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 12 North America Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 13 U.S. Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 14 U.S. Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
  • Table 15 U.S. Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 16 Canada Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 17 Canada Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
  • Table 18 Canada Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 19 Europe Gene Therapy Market by Country, 2018 - 2030 (USD Million)
  • Table 20 Europe Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
  • Table 21 Europe Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 22 Europe Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 23 Germany Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
  • Table 24 Germany Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 25 Germany Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 26 UK Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
  • Table 27 UK Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 28 UK Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 29 Switzerland Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
  • Table 30 Switzerland Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 31 Switzerland Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Gene Therapy Market by Country, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 36 China Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 37 China Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
  • Table 38 China Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 39 Japan Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 40 Japan Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
  • Table 41 Japan Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 42 South Korea Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 43 South Korea Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
  • Table 44 South Korea Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 45 Australia Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 46 Australia Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
  • Table 47 Australia Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 48 RoW Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 49 RoW Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
  • Table 50 RoW Gene Therapy Market by Indication, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Market Formulation & Validation
  • Fig. 5 Gene Therapy Market Segmentation
  • Fig. 6 Porter's Five Forces Analysis
  • Fig. 7 Regional Marketplace: Key Takeaways
  • Fig. 8 Global Gene Therapy Market for Lentivirus, 2018 - 2030 (USD Million)
  • Fig. 9 Global Gene Therapy Market for AAV, 2018 - 2030 (USD Million)
  • Fig. 10 Global Gene Therapy Market for RetroVirus & gamma RetroVirus, 2018 - 2030 (USD Million)
  • Fig. 11 Global Gene Therapy Market for Modified Herpes Simplex Virus, 2018 - 2030 (USD Million)
  • Fig. 12 Global Gene Therapy Market for Adenovirus, 2018 - 2030 (USD Million)
  • Fig. 13 Global Gene Therapy Market for Other Vector Type, 2018 - 2030 (USD Million)
  • Fig. 14 Global Gene Therapy Market for Acute Lymphoblastic Leukemia (ALL), 2018 - 2030 (USD Million)
  • Fig. 15 Global Gene Therapy Market for Inherited Retinal Disease, 2018 - 2030 (USD Million)
  • Fig. 16 Global Gene Therapy Market for Large B-cell Lymphoma, 2018 - 2030 (USD Million)
  • Fig. 17 Global Gene Therapy Market for Melanoma (lesions), 2018 - 2030 (USD Million)
  • Fig. 18 Global Gene Therapy Market for Beta-Thalassemia Major/SCD, 2018 - 2030 (USD Million)
  • Fig. 19 Global Gene Therapy Market for Spinal Muscular Atrophy (SMA), 2018 - 2030 (USD Million)
  • Fig. 20 Global Gene Therapy Market for Others, 2018 - 2030 (USD Million)
  • Fig. 21 Global Gene Therapy Market for Intravenous, 2018 - 2030 (USD Million)
  • Fig. 22 Global Gene Therapy Market for Others, 2018 - 2030 (USD Million)
  • Fig. 23 Regional Outlook, 2022 & 2030
  • Fig. 24 North America Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 25 U.S. Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 26 Canada Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 27 Europe Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 28 Germany Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 29 UK Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 30 Switzerland Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 31 Asia Pacific Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 32 Japan Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 33 China Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 34 Australia Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 35 South Korea Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 36 Rest of the world Gene Therapy Market 2018 - 2030 (USD Million)